Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > NanCogenics Invited to Present Novel Technology for the Targeted Delivery of Cancer Therapeutics at BioNanoMed 2013, the Fourth Annual International Conference

Abstract:
Officials at NanCogenics, Inc. announced today that Co-Founder Dr. Jim Klostergaard has been invited to present at the upcoming BioNanoMed 4th International Conference on Nanotechnology, Medicine and Biology, to be held March 13-15, in Krems, Austria. Dr. Klostergaard will speak about a paper titled "A Cancer Treatment Modality Based on the Tumor-Specific Localization of Cancer Therapeutics", which will discuss the application of the company's tumor targeting platform as a clinical procedure.

NanCogenics Invited to Present Novel Technology for the Targeted Delivery of Cancer Therapeutics at BioNanoMed 2013, the Fourth Annual International Conference

Houston, TX | Posted on March 6th, 2013

This prestigious three day congress will bring together academia, industry, governmental and non-governmental institutions to discuss current, emerging and future trends of the converging fields of Nanotechnology, Biotechnology and Medicine. The theme for BioNanoMed 2013 is Nanotechnology Enables Personalized Medicine which focuses on current and developing efforts to bring an individualized approach to cancer therapy.

The NanCogenics technology platform, as envisioned by Co-Founders, Dr. Klostergaard, Professor of Molecular and Cellular Oncology at the University of Texas M D Anderson Cancer Center (Houston, TX), and Charles Seeney, Managing Director of NewTech Development (Edmond, OK), enables the emerging trend to personalized medicine. The nanotechnology-based platform is based on designed therapeutic nano prodrug constructs that respond to external magnetic forces in targeting tumor sites, generating effective anti-tumor results without harm to normal tissue or organs, thereby substantially reducing the feared side effects and complications often attributed to chemotherapy. The Co-Founders believe that the advancement of this platform to the clinic will lead to significant improvements, not only in cancer chemotherapy, but also as a means of targeting a range of new cancer therapeutics now under development.

The Company's newly recruited President and CEO, states that "this conference provides a significant first step in our efforts to raise the awareness of the potential of magnetic localization, and the impact NanCogenics can have in the emerging field of nanomedicine". He further states that the Company is moving forward with funding mechanisms to support business objectives and anticipated future FDA IND filings.

####

About NanCogenics, Inc.
Overall, NanCogenics sees itself as a resource for enhanced and improved therapeutic performance, with more drug penetration occurring at the target site and less to normal tissue. The capacity to localize cytotoxic drugs in high concentrations at the tumor site will lead to more effective treatment regimens, greater patient compliance to therapy and improved outcomes, such as patient quality of life and survival rates.

Safe Harbor Statement

Certain statement included in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of products and services, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact and involve risks and uncertainties. The company's expectations regarding future revenues are dependent upon the ability to develop and supply products and services that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions are generally considered forward-looking statements. These statements reflect current expectations.

For more information, please click here

Contacts:
NCGI
Charles Seeney

Ph: 855.842.6771

Copyright © NanCogenics, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Aerotech X-Y ball-screw stage for economical high performance Planar positioning April 16th, 2014

Energy Research Facility Construction Project at Brookhaven Lab Wins U.S. Energy Secretary's Achievement Award April 16th, 2014

Malvern reports on the publication of the 1000th peer-reviewed paper to cite NanoSight’s Nanoparticle Tracking Analysis, NTA April 16th, 2014

Biologists Develop Nanosensors to Visualize Movements and Distribution of Plant Stress Hormone April 15th, 2014

Nanomedicine

Nanobiotix Appoints Thierry Otin as Head of Manufacturing and Supply April 15th, 2014

PAM-XIAMEN Offers UV LED wafer April 15th, 2014

Nanocrystalline cellulose modified into an efficient viral inhibitor April 15th, 2014

Targeting cancer with a triple threat: MIT chemists design nanoparticles that can deliver three cancer drugs at a time April 15th, 2014

Announcements

Aerotech X-Y ball-screw stage for economical high performance Planar positioning April 16th, 2014

Energy Research Facility Construction Project at Brookhaven Lab Wins U.S. Energy Secretary's Achievement Award April 16th, 2014

Malvern reports on the publication of the 1000th peer-reviewed paper to cite NanoSight’s Nanoparticle Tracking Analysis, NTA April 16th, 2014

Biologists Develop Nanosensors to Visualize Movements and Distribution of Plant Stress Hormone April 15th, 2014

Appointments/Promotions/New hires/Resignations/Deaths

Nanobiotix Appoints Thierry Otin as Head of Manufacturing and Supply April 15th, 2014

Industry Veteran Fergus Clarke Joins Picodeon as CEO: Appointment comes as Picodeon prepares for growth April 8th, 2014

Peter B. Littlewood appointed Director of Argonne National Laboratory March 26th, 2014

Global 450 consortium announces new general manager of internal operations: TSMC’s Cheng-Chung Chien Receives Unanimous Support, Brings History of Innovation and Efficiency to Global Consortium of Companies Driving Industry Transition to 450mm Wafer Technology March 26th, 2014

Events/Classes

Engineers develop new materials for hydrogen storage April 15th, 2014

Near-field Nanophotonics Workshop in Boston April 14th, 2014

LetiDays Grenoble to Present Multiple Perspectives on Development, Challenges and Markets for the IoT April 14th, 2014

Iran to Hold 2nd National Conference on Nanotechnology in Power, Energy Industries April 13th, 2014

NanoNews-Digest
The latest news from around the world, FREE







  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE